ALMS
COM:ALUMIS
Alumis
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
alumis.comlinkedin
alumis-cofounding date
Jan 01, 2021ipo date
Feb 22, 2021
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibi...Show More